Business Wire1mon
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
The primary efficacy and safety endpoints of the trial ... Authorized Use of LAGEVRIO TM (molnupiravir) in the U.S. LAGEVRIO (molnupiravir) is authorized for use under an Emergency Use ...
BBC3y
Molnupiravir: First pill to treat Covid gets approval in UK
Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator ...
The New Yorker3y
How Will the COVID Pills Change the Pandemic?
The Emory researchers named their drug molnupiravir, after Mjölnir—the hammer of Thor. It turns out that this was not hyperbole. Last month, Merck and Ridgeback announced that molnupiravir ...
BBC3y
Covid: First UK patients given take-at-home pill
Molnupiravir was the first oral antiviral ... Combined with the results from the first part of the trial, it reduced the overall efficacy of the treatment from 50% to 30%. Drug regulators in ...